Core Viewpoint - The company assesses that the recent EU policy changes regarding public procurement contracts will have a limited and manageable impact on its European business operations [1] Group 1: Company Strategy and Response - The company has been proactively upgrading its global supply chain strategy since 2018, focusing on diversifying production and service nodes globally [1] - The establishment of a subsidiary in Poland in 2018 and the European regional headquarters in the Netherlands in 2024 exemplifies the company's forward-looking global strategy [1] - The company has over 500 high-end medical devices servicing more than half of the EU member states, indicating a strong localized operational framework [1] Group 2: Market Opportunities - The company identifies dual structural opportunities in the European market: a replacement demand cycle in mature markets like Western Europe and emerging demand in Eastern Europe for high-end imaging equipment [1] - As of 2024, revenue from the European market accounts for approximately 3.75% of the company's total revenue, with most projects falling below the €5 million threshold set by the new EU policy [1] Group 3: Future Outlook - The company plans to continue diversifying its market presence while strengthening its operations in North America, Asia-Pacific, and Latin America [1] - The focus will remain on innovation and collaboration with leading academic and clinical institutions to enhance product value [1] - To mitigate potential long-term trade barriers, the company aims to accelerate the establishment of production and service centers in key overseas regions [1]